Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
China NT Pharma Group Co., Ltd. ( (HK:1011) ) has shared an announcement.
China NT Pharma Group Co., Ltd. reported its unaudited interim results for the first half of 2025, showing a significant decrease in revenue from RMB 31,297,000 in 2024 to RMB 11,995,000 in 2025. Despite an increase in gross profit, the company faced a comprehensive loss due to higher finance costs and changes in the fair value of financial assets, impacting its overall financial performance and market positioning.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is primarily engaged in providing healthcare solutions and has a market focus on improving access to essential medications.
Average Trading Volume: 1,042,599
Technical Sentiment Signal: Buy
Current Market Cap: HK$532.7M
For detailed information about 1011 stock, go to TipRanks’ Stock Analysis page.